Roche Holding AG (SWX:ROG)
322.30
+1.60 (0.50%)
Inactive · Last trade price on Mar 16, 2026
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
613.62K CHF
Profits / Employee
124.75K CHF
Market Cap
257.46B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Roche Holding AG News
- 3 days ago - Louth GAA FL Round-up - Div 2: O’Raghallaighs pick up vital points as Roche open six-point lead at the top - Independent Ireland
- 3 days ago - Exelixis Announces STELLAR-303 Trial Results For Zanzalintinib Combination - Nasdaq
- 6 days ago - The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs - WSJ
- 6 days ago - U.S. opens tariff probe targeting Germany's drug pricing policies - CNBC
- 7 days ago - Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion - GuruFocus
- 7 days ago - FDA Accepts Genentech's SBLA For Lunsumio-Polivy In LBCL; Decision Slated For February 2027 - Nasdaq
- 7 days ago - FDA accepts supplemental Biologics License Application for Roche's Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma - GlobeNewsWire
- 7 days ago - FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma - Business Wire